Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial (2023)

First Author: Freeman S

Attributed to: Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Acute Myelodi Leukaemia (and Solid Tumours). funded by MRC

No abstract provided

Type: Journal Article/Review

Parent Publication: Blood

Issue: 20